Introduction
Mucinous adenocarcinoma (MAC) is an epithelial malignancy characterized by distinctive cells secreting abundant extracellular mucin.
1 SRCC is a rare subtype of MAC with ringlike cells in which the nucleus is displaced to the periphery by substantial intracytoplasmic mucin. 2 Verhulst et al 3 reported that colorectal SRCC is rare, and accounts for <1% of all colorectal adenocarcinoma cases. Colorectal SRCC is associated with younger age, higher tumor grade, and poorer outcomes, compared with conventional adenocarcinoma. [4] [5] [6] [7] [8] [9] The World Health Organization defines SRCC as an adenocarcinoma with ≥50% SRCs in the tumor. 10 However, whether prognosis is associated with the SRC ratio in colorectal MAC-SRC remains unclear. Indeed, colorectal MAC comprising low SRC amounts (<50%) has been seldom evaluated previously. Therefore, it is essential to assess the
Follow-up
The patients were followed up clinically every 3 months for 1 year, every 6 months for the subsequent 2 years, and annually thereafter. Tumor progression was defined either pathologically or radiologically as local recurrence (recurrence close to the primary tumor bed or at the anastomotic stoma) and distant metastases (relapses in regions that could not be regarded as local recurrence).
statistical analysis
Research end points were PFS and OS. The Kaplan-Meier method was used to generate survival curves, with the logrank test employed for comparison. Meanwhile, the cutoff point for the SRC ratio affecting survival was calculated using Cutoff Finder application. 12 A Cox regression model was used to evaluate predictive factors of PFS and OS. Two-sided P<0.05 was considered statistically significant. PFS was defined as the time from pathological diagnosis to tumor progression or death. OS was determined as the time interval between pathological diagnosis and death due to any reason or last follow-up. Statistical analyses were conducted with SPSS version 22.0 (IBM Corporation, Armonk, NY, USA).
Results

Patient characteristics
A total of 95 patients were enrolled in the present study. 
Pathological features
According to the Cutoff Finder software, 35% was considered the optimal cutoff point for the SRC ratio ( Figure 1 Waterfall plot of optimal dichotomization. Classification was done using the SRC ratio status; optimal cutoff was assessed for the events of progression and death. Abbreviations: R, ratio; P, progression; D, death; OR, odds ratio; MaC-sRC, mucinous adenocarcinoma with sRCs; sRC, signet ring cell. 
Prognostic factors of PFs and Os
Discussion
This is one of the few studies focusing on the predictive value of SRC ratio in colorectal MAC-SRC patients with multiple prognostic factors. Our findings showed that SRC ratio ≥35% and distant metastasis indicated poor prognosis in colorectal MAC-SRC, while pre-CT and pre-RT improved survival. Colorectal MAC has a dismal prognosis compared to classical adenocarcinoma. 1, 13 The reported 5-year OS rate is significantly lower for colorectal MAC than classical 13 demonstrated that colorectal MAC patients with SRCs show poorer outcome than those without. Moreover, SRCC is considered an independent predictive factor of dismal prognosis. 14, 15 Reportedly, the 5-year OS rate of colorectal SRCC ranges from 0 to 31%, 5, 13, [15] [16] [17] obviously lower than that of the conventional colorectal MAC (range 48.0-69.0%). 9, 13, 17 In the current analysis, the 5-year OS rate in colorectal MAC-SRC patients was 42.5%, falling between MAC and SRCC rates. Interestingly, a previous study revealed that the morphological and molecular characteristics of colorectal MAC with low amounts of SRCs (<50%) are similar to those of SRCC. 18 Therefore, we hypothesized that the SRC ratio is associated with the dismal prognosis of colorectal MAC-SRC. As shown above, 35% was the cutoff point of the SRC ratio. The above results showed that the 5-year PFS and OS rates in patients with SRC ratios <35% were higher than those of individuals with ≥35% (PFS, 37.0 vs 14.7%, P=0.048; OS, 50.7 vs 33.2%, P=0.035, respectively). Importantly, the SRC ratio was an independent prognostic factor of PFS (P=0.014, HR=1.917, 95% CI 1.140-3.225) and OS (P=0.032, HR=2.500, 95% CI 1.082-5.781). In general, refining the impact of the SRC ratio on survival could help implement more aggressive 
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Kong et al treatments for patients with poor prognosis, and provides a basis for building an optimal prognostic system. Therefore, pathologists are advised to identify any SRC component and focus intensively on patients with colorectal MAC-SRC, especially those with low amounts of SRCs. Based on our findings, 35% might be an optimal cutoff point for predicting the outcome of colorectal MAC-SRC.
In agreement with previous colorectal SRCC data, 4, 5, [7] [8] [9] colorectal MAC-SRC patients were commonly diagnosed at an advanced stage in this study, with distant metastasis or lymph node metastasis. In a previous study examining 59 patients, 58 (98.3%) individuals had T3/T4 lesions, 52 (88.1%) showed lymph node metastasis, and 14 (23.7%) had distant metastasis. 5 In line with previous reports, almost all cases (96.3%) in the current study were diagnosed as stage T3 or T4, with 91.4% and 29.3% showing lymph node involvement and distant metastasis, respectively. Early diagnosis might be challenging because colorectal MAC-SRC is merely asymptomatic in the initial stage. However, SRCs are histologically more aggressive due to the absence of cellto-cell adhesion, which leads to a high tendency of metastasis. 7, 9, 19 The reported incidence of peritoneal metastasis in colorectal SRCC is 38%, with a combined rate at other sites, including the liver, lung, bone, and brain, of only 18.5%. 4 Additionally, colorectal tumors with <50% SRCs have a predisposition (75.0%) to metastasize to the peritoneum and ovaries. 19 Similarly, we observed that colorectal MAC-SRC metastasized predominantly to the peritoneum (40.7%) and ovaries (29.6%), and rarely to the liver, lung, and bone (18.5% combined). For the 38 patients with <35% SRCs, the rate of peritoneal and ovarian metastasis was 18.4%, while 21.1% was obtained for the 57 patients with ≥35% SRCs. Hence, a high peritoneal and ovarian metastasis rate and a relatively low incidence of liver or lung metastasis may constitute a unique characteristic of colorectal MAC-SRC. This might be ascribed to poor prognosis since the patients cannot be treated by radical surgery to diffuse the peritoneal metastasis. In the current study, distant metastasis was an independent predictor of PFS (P=0.044, HR=1.750, 95% CI 1.015-3.017) and OS (P=0.000, HR=3.219, 95% CI 1.676-6.181), indicating the poor outcome of MAC-SRC.
Previous studies demonstrated that colorectal SRCC is more common in younger individuals (≤40-year-old) than non-SRC MAC. 4, 5, 7, 14 The reported mean age of colorectal SRCC patients is 48.1 years, while 57.4 years was found for colorectal MAC. 20 Young age (≤40-year-old) was shown to be an independent predictive factor of disease outcome in a previous study. 7 In this work, the median age of colorectal MAC-SRC patients was 44 years, corroborating previous reports. However, no significant association was found between age and PFS (P=0.871) or OS (P=0.959). This might be explained by the fact that all colorectal MAC-SRC patients were enrolled in this analysis, including those with reduced SRC amounts (<50%).
Fu et al 14 and Inamura et al 15 reported that a female predominance is common (range 56-73.4%), with females having a poor outcome in colorectal SRCC (P<0.001), 14 while males show prevalence in other studies (range 64.4-68.2%). 4, 5, 20 Meanwhile, others found no significant difference between males and females. 5, 17 In the current work, females and males had equal rates (49.5 vs 50.5%), with no significant association between gender and PFS (P=0.199) or OS (P=0.128), corroborating the findings of Wang et al 5 and Hugen et al. 17 Studies also showed a right-side predominance (44.0%) in colorectal SRCC, 21 while others consider the colonic site an independent prognostic factor (P=0.012).
14 As shown above, all sites were involved in colorectal MAC-SRC, with rectal MAC-SRC being rather common (62.1%), in line with the literature. 4, 5 Moreover, Tawadros et al 7 demonstrated that rectal cancer morbidity in young patients (<40) increases with an annual change of +3.6%; in addition, cancers in this population are more likely to exhibit the SRC component (about 3.6:1). In this study, young patients with rectal MAC-SRC (≤40-year-old) had a 5-year OS rate of 40.2%, while the median SRC ratio was 55%.
The 8th AJCC Cancer Staging recommends pre-CEA and LVI as prognostic and predictive factors of colorectal cancer. 11 Indeed, pre-CEA is considered an independent prognostic factor of colorectal cancer. 22 In the current cohort, pre-CEA had a significant impact on OS as assessed by univariate analysis (5-year OS, 38.4 vs 42.0%); however, it was not an independent predictive factor of MAC-SRC (P=0.100). Meanwhile, LVI is considered an independent prognostic factor of SRCC (HR=2.888, 95% CI 1.115-7.483). 5 In agreement, Barresi et al 23 showed that VI, assessed by IHC staining, is an independent prognostic factor of disease-free survival (P=0.02) and cancer-specific survival (P=0.001). In the current cohort, LVI had a significant impact on PFS (P=0.032) but was not an independent predictive factor of MAC-SRC (P=0.112). The pathological characteristics were assessed by H&E rather than IHC staining in this work, and we could not distinguish VI from LVI. Thus, IHC staining should be applied in further studies with larger sample sizes.
To the best of our knowledge, surgical resection is the gold standard treatment for resectable colorectal cancer. Nevertheless, SRCC cases display greater intolerability to surgery than non-SRCC ones, with recurrence or death 
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sRC ratio predicts poor survival in colorectal MaC-sRC within a short period of time post-surgery (24.5 vs 13.0%, P=0.001).
14 Here, we observed that pre-CT and pre-RT could improve survival in colorectal MAC-SRC, unlike post-CT and post-RT. In contrast, a large population-based study in the Netherlands observed longer survival in stage III SRCC patients treated with post-CT; however, a significant interaction between SRCC and chemotherapy was not observed (P=0.54). 17 In addition, neither pre-RT nor post-RT was found to affect survival in SRCC. 4 Due to its rarity, studies exploring the optimal treatment strategy for colorectal SRCC are scarce. However, because of the aggressive nature of SRC, it is necessary to gain insights into the potential treatment options to enhance survival in these patients.
Limitations
This retrospective study had some limitations. First, it was a single-center clinical research that only enrolled 95 patients with colorectal MAC-SRC due to the rarity of the disease. Thus, multicenter studies are warranted for further exploring the disease. Secondly, 14 patients underwent no surgery and >10% had missing T-and N-stage data in this retrospective analysis, which might result in selection bias. Thirdly, we provided only limited novel information about the morphological and molecular characteristics of SRCs, which necessitate additional studies.
Conclusion
Overall, we assessed the long-term survival outcomes and identified the SRC ratio as an independent prognostic factor of colorectal MAC-SRC. Moreover, M stage might be negatively correlated with prognosis, while pre-CT and pre-RT could prolong survival independently. However, further studies are required to confirm these findings and explore the molecular mechanisms underlying the SRC components that affect survival.
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